Ophthalmology Times45m
Stealth BioTherapeutics reaches 50 percent enrollment target in phase 3 ReNEW study
The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of ...
Ophthalmology Times1h
Preclinical study of KIO-104 in a proliferative vitreoretinopathy model accepted for poster presentation at ARVO 2025
The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.
Ophthalmology Times1h
Case report: Bilateral retinal detachments in a 19-year-old
The authors commented that the patient’s "age, relative acute onset, and lack of medical history make this an atypical ...